Female doctor

GORE® VIABAHN® Device family

Join the next generation of care in the treatment of aortoiliac occlusive disease

The latest generation of covered stent grafts

GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft)
GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface* (VIABAHN® Device)
 

VBX Stent Graft

Decide with data

Five-year follow-up shows the VBX Stent Graft continues to be a long-term durable treatment option for complex aortoiliac occlusive disease (AIOD).1

The Gore VBX FLEX Clinical Study three-year follow-up found the VBX Stent Graft to be a robust and durable treatment option for AIOD.2  Now, sustained patient benefit and durability are demonstrated through five years.

Physician-initiated five-year VBX Stent Graft follow-up
 

Objective and methodology1
 

  • This physician-initiated study enrolled 59 patients from three participating centers that were representative of the VBX FLEX Study three-year follow-up cohort. 28 patients completed the five-year follow-up.
  • The primary durability endpoint was long-term primary patency.

 

DURABLE CLINICAL OUTCOMES THROUGH FIVE YEARS1:

 

SUSTAINED PATIENT BENEFIT THROUGH FIVE YEARS1:

 

The case for long-term durable clinical outcomes:

Case study 1: Treating severe aortoiliac occlusive disease (AIOD) at the aortic bifurcation
Case study 2: Restoring flow to a patient with stenosis at the aortoiliac bifurcation
Case study 3: Restoring flow in a patient with severe claudication and focal iliac calcification

 

VIABAHN® Device

Proven patency with unmatched versatility

VIABAHN® Device

VIABAHN® Device outcomes in iliac occlusive disease

Prospective, multicenter, single-arm study

53 patients (61 limbs) with iliac artery occlusion or stenosis (mean lesion length: 6.9 cm; 48% of limbs in the external iliac artery)

91% primary patency at one year. 95% secondary patency at one year

* As used by Gore, Heparin Bioactive Surface refers to Gore's proprietary CBAS® Heparin Surface. 
† (P < .001) Statistically significant change from pre-procedure.

  1. Holden A, Takele E, Hill A, et al. Long-term follow-up of subjects with aortoiliac occlusive disease treated with the VIABAHN VBX balloon expandable endoprosthesis. Presented at Cardiovascular & Interventional Radiological Society of Europe (CIRSE) 2022; September 10-14, 2022; Barcelona, Spain. CardioVascular & Interventional Radiology 2022;45:Supplement:S147. Abstract 301.1.
  2. Panneton JM, Bismuth J, Gray BH, Holden A. Three-year follow-up of patients with iliac occlusive disease treated with the Viabahn Balloon-Expandable Endoprosthesis. Journal of Endovascular Therapy 2020;27(5):728-736.
  3. Lammer J, Dake MD, Bleyn J, et al. Peripheral arterial obstruction: prospective study of treatment with a transluminally placed self-expanding stent graft. Radiology 2000;217(1):95-104.

22703753-EN